Evidence map›Paper›PMID 37781993›Full record

ArticleAdvanced healthcare materials2023

Adipose-Derived Stromal Cells Preserve Pancreatic Islet Function in a Transplantable 3D Bioprinted Scaffold.

Shadab Abadpour, Essi M Niemi, Linnea Strid Orrhult, Carolin Hermanns, Rick de Vries, Liebert Parreiras Nogueira, Håvard Jostein Haugen, Dag Josefsen, Stefan Krauss, Paul Gatenholm and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Shadab AbadpourDepartment of Transplant Medicine, Oslo University Hospital, Oslo, 0372, Norway.ORCID 0000-0002-7567-7871
Essi M NiemiInstitute for Surgical Research, Oslo University Hospital, Oslo, 0372, Norway.
Linnea Strid Orrhult3D Bioprinting Center, WWSC, Department of Chemistry and Chemical Engineering, Chalmers University of Technology, Gothenburg, 41296, Sweden.
Carolin HermannsMERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, 6229, The Netherlands.
Rick de VriesMERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, 6229, The Netherlands.
Liebert Parreiras NogueiraInstitute for Clinical Dentistry, University of Oslo, Oslo, 0317, Norway.
Håvard Jostein HaugenInstitute for Clinical Dentistry, University of Oslo, Oslo, 0317, Norway.
Dag JosefsenSection for Cellular Therapy, Radiumhospitalet, Oslo University Hospital, Oslo, 0379, Norway.
Stefan KraussHybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, 0372, Norway.
Paul Gatenholm3D Bioprinting Center, WWSC, Department of Chemistry and Chemical Engineering, Chalmers University of Technology, Gothenburg, 41296, Sweden.
Aart van ApeldoornMERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, 6229, The Netherlands.
Hanne ScholzDepartment of Transplant Medicine, Oslo University Hospital, Oslo, 0372, Norway.
Oslo University Hospital · NOUnited Nations University – Maastricht Economic and Social Research Institute on Innovation and Technology · NLUniversity of Oslo · NOChalmers University of Technology · SESandvik (Norway) · NO

Funding

Diabetesforbundet 2019027Norges Forskningsråd 262613Norges Forskningsråd IPN 317790
6 · The paper itself

Abstract

Intra-portal islet transplantation is currently the only clinically approved beta cell replacement therapy, but its outcome is hindered by limited cell survival due to a multifactorial reaction against the allogeneic tissue in liver. Adipose-derived stromal cells (ASCs) can potentially improve the islet micro-environment by their immunomodulatory action. The challenge is to combine both islets and ASCs in a relatively easy and consistent long-term manner in a deliverable scaffold. Manufacturing the 3D bioprinted double-layered scaffolds with primary islets and ASCs using a mix of alginate/nanofibrillated cellulose (NFC) bioink is reported. The diffusion properties of the bioink and the supportive effect of human ASCs on islet viability, glucose sensing, insulin secretion, and reducing the secretion of pro-inflammatory cytokines are demonstrated. Diabetic mice transplanted with islet-ASC scaffolds reach normoglycemia seven days post-transplantation with no significant difference between this group and the group received islets under the kidney capsules. In addition, animals transplanted with islet-ASC scaffolds stay normoglycemic and show elevated levels of C-peptide compared to mice transplanted with islet-only scaffolds. The data present a functional 3D bioprinted scaffold for islets and ASCs transplanted to the extrahepatic site and suggest a possible role of ASCs on improving the islet micro-environment.

Indexed as

Diabetes Mellitus, ExperimentalInsulin-Secreting CellsIslets of LangerhansIslets of Langerhans TransplantationAnimalsHumansInsulinInsulin SecretionMiceStromal CellsInsulin3D bioprintingalginateASCin vivoisletsnanocellulosescaffolds

Identifiers

PMID37781993
PMCPMC11469278
OpenAlexW4387241878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.